Skip to content
akaturk Academic measurement
Search

Article detail · 2019 · article

The safety and effectiveness of 0.16 mg bevacizumab plus or minus additional laser photocoagulation in the treatment of retinopathy of prematurity

ISSN0301-4738
YÖKSİS OpenAlex Open access · diamond
Year2019
Citations12OpenAlex
Citations9Semantic Scholar · 1 influential
Percentile%82.6
FWCI1.561.00 = world average
Scopus (SJR)Q3
WoS (JCR)Q4

Data source split

  • YÖKSİSYÖKSİS article record
  • YÖKSİS venueIndian Journal of Ophthalmology
  • Catalog match (ISSN)Indian Journal of Ophthalmology
  • OpenAlexOpenAlex enrichment (abstract, citations, topics)
  • Semantic Scholarcitation count (not merged with OpenAlex)

Abstract

OpenAlex English

Purpose: Retinopathy of prematurity (ROP) is the leading cause of preventable blindness in premature infants. Antivascular endothelial growth factor (anti-VEGF) therapy has been used increasingly in treatment as a pharmacological alternative to laser therapy. In this study, we evaluate the results of low-dose anti-VEGF treatments. Methods: Design: Retrospective--observational study. Infants who had been evaluated for ROP disease between February 2016 and February 2017 were assessed. We retrospectively reviewed the ROP stages, treatment results, and complications. Laser photocoagulation (LPC) and intravitreal bevacizumab (0.16 mg IVB) were used for treatment and fundus fluorescein angiography (FFA) was also performed in some of the cases. Results: IVB was applied to 43 infants. A macular hole was seen in one infant's eye after IVB. LPC was applied to avascular areas in 21 infants. In three patients, persistence of the disease was observed after administration of a low dose of IVB. Additional LFK was performed in these patients. None of the infants who received LPC had any complications. Conclusion: IVB is increasingly becoming the first-line treatment for ROP. For severe ROP, 0.16 mg IVB is effective. Using LPC to treat avascular areas after 70 weeks' gestational age (GA) may decrease the risk of late recurrence and appears to be a safe treatment to use.

Topics

Citations

OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.

12citationsOpenAlex · cited_by_count (cache / database)

1 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).

  1. 2023 RESULTS OF TWO CASES WITH DISTINCT COMPLICATIONS DUE TO INTRAVITREAL BEVACIZUMAB IN RETINOPATHY OF PREMATURITYCitations 5 · OpenAlex

Authors

3
  1. MÜBERRA AKDOĞAN AFYONKARAHİSAR SAĞLIK BİLİMLERİ ÜNİVERSİTESİ 1
  2. SADIK GÖRKEM ÇEVİK 2
  3. ÖZLEM ŞAHİN 3